Vusura Technology LLC

Vusura Technology LLC appears to be a misnomer in the provided patent litigation data, likely referring to Visura Technologies, Inc., a privately held medical device company. Founded in 2015 by David Marmor, Visura Technologies is headquartered in Bloomington, Minnesota, United States. As of July 2024, the company had approximately 5-9 employees and has raised $6.38M in funding over three rounds. In 2023, Visura Technologies also entered a joint venture with YKK Corporation of America to launch Evevo Manufacturing LLC, a contract manufacturer for emerging medical device companies.

Visura Technologies specializes in advanced visualization solutions to enhance the safety and effectiveness of transesophageal echocardiogram (TEE) probe intubations. Their flagship product, the TEECAD System, is the first FDA-cleared, disposable camera that attaches to a TEE probe, providing physicians with real-time visualization during placement. This system aims to improve first-pass success rates and reduce the risk of injuries associated with traditional blind intubation methods.

Based on the provided case data, Vusura Technology LLC (likely Visura Technologies, Inc.) has a litigation posture of an operating company defending against patent assertions. They have been recorded as a defendant in one case before the Patent Trial and Appeal Board (PTAB) and have no recorded instances as a plaintiff. This suggests they are primarily focused on developing and commercializing their medical device technology.

The single tracked case, "Vusura Technology LLC v. Cisco Systems Inc.", was filed in the U.S. District Court for the Eastern District of Texas on August 25, 2025. The dispute alleges that Cisco's Webex Contact Center infringes three patents related to virtual call center architecture and methods for presenting content with a telephone call. This indicates that the patent litigation is not directly related to Visura Technologies' core medical device products, but rather involves a different technological area, possibly suggesting an acquired patent portfolio or a separate entity with a similar name.